Stay calm and carry on: How to implement the updated ABPI codeDon’t panic – that’s the message from one ABPI code expert who tells Amanda Barrell it’s time to Share XStay calm and carry on: How to implement the updated ABPI codehttps://pharmaphorum.com/views-analysis-market-access/how-to-implement-the-updated-abpi-code/
VPAS: Progress two years in and opportunities to improve over next three yearsIn the final instalment of our series reviewing the the 2019 Voluntary Scheme for Branded Medicines Pricing and Share XVPAS: Progress two years in and opportunities to improve over next three yearshttps://pharmaphorum.com/views-analysis-market-access/vpas-progress-two-years-in-and-opportunities-to-improve-over-next-three-years/
VPAS: Achievement so far on objectives for the economy and innovationIn the third part of this series taking stock of the 2019 Voluntary Scheme for Branded Medicines Pricing and Share XVPAS: Achievement so far on objectives for the economy and innovationhttps://pharmaphorum.com/views-analysis-market-access/vpas-achievement-so-far-on-objectives-for-the-economy-and-innovation/
Why we need the human element of remote clinical trialsOver the last year, we’ve noticed that “connectivity” doesn’t always equate to “connected” – and that’s just as Share XWhy we need the human element of remote clinical trialshttps://pharmaphorum.com/views-analysis-patients/why-we-need-the-human-element-of-remote-clinical-trials/
Dilemma for Biden as Woodcock’s audition for FDA chief stumblesThe change of administration in the US has also seen a new leader at the FDA, with Dr Share XDilemma for Biden as Woodcock’s audition for FDA chief stumbleshttps://pharmaphorum.com/views-and-analysis/dilemma-for-biden-as-woodcocks-audition-for-fda-chief-stumbles/
VPAS: Achievements so far on affordabilityIn the second part of this series taking stock of the 2019 Voluntary Scheme for Branded Medicines Pricing Share XVPAS: Achievements so far on affordabilityhttps://pharmaphorum.com/views-analysis-market-access/vpas-achievements-so-far-on-affordability/
Not every cough is COVID – MSD UK’s lung cancer campaignFor World Cancer Day, David Long, business unit director of Oncology at MSD UK tells pharmaphorum about the Share XNot every cough is COVID – MSD UK’s lung cancer campaignhttps://pharmaphorum.com/views-analysis-oncology/world-cancer-day-msd-uk-lung-cancer-campaign/
VPAS: Achievement so far on objectives for patientsThe UK has a voluntary agreement that was struck by the government and NHS England (now referred to Share XVPAS: Achievement so far on objectives for patientshttps://pharmaphorum.com/views-analysis-market-access/vpas-achievement-so-far-on-objectives-for-patients/
Casting aside CRISPR scissors and making a point with base editorsDr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at Share XCasting aside CRISPR scissors and making a point with base editorshttps://pharmaphorum.com/r-d/views-analysis-r-d/immune-cell-therapies-crispr-cas9-gene-editing/
